Vol. 8, Issue 1 (2019)
Formulation and evaluation of bilayer tablets of clarithromycin and omeprazole against Helicobacter pylori infection
Gaurav Kumar, Vivek Jain, Shradha Shende and Prabhat Jain
In the current study a successful attempt was made to formulate bilayer floating tablets of clarithromycin and omeprazole by direct compression method containing loading dose, superdisintegrants in immediate release layer and maintenance dose, rate controlling polymers and gas generating agents in floating layer. The extended release was prepared by direct compression method using HPMC K15, HPMC K4, PVP K30, as sustained release polymer and sodium bicarbonate as gas generating agent to reduce floating lag time. Immediate release layer were prepared by direct compression using sodium starch glycolate, Croscarmellose sodium, crospovidone as super disintegrant. Gastro retentive floating drug delivery systems have been designed to increase its residence time in the stomach. The granules were evaluated for bulk density, tapped density, compressibility index, and hausner’s ratio. The granules showed satisfactory flow properties. The optimized tablets were compressed to obtain bilayer tablets. The tablets were evaluated for various physicochemical parameters and dissolution study. Further, the bilayer tablets were subjected to accelerated stability study. The omeprazole tablet showing more than 99.45 % release in 15 min and clarithromycin tablet showing more than 99.76 % release at the end of 12 h of initial lag time were compressed one above the other to obtain bilayer tablet. The similar release pattern was observed with the bilayer tablets as that of individual tablets. The bilayer tablets were found to be stable at the end of 6 months storage period as per ICH guidelines. Both the layers of the bilayer formulation showed desired drug release at the end of time period.
How to cite this article:
Gaurav Kumar, Vivek Jain, Shradha Shende, Prabhat Jain. Formulation and evaluation of bilayer tablets of clarithromycin and omeprazole against <em>Helicobacter pylori</em> infection. Pharma Innovation 2019;8(1):407-412.